Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are na ïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS).

CONCLUSIONS: Guselkumab demonstrated superiority over FAE in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis through 24 weeks. PMID: 31705526 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31705526?dopt=Abstract

Source: The British Journal of Dermatology - November 8, 2019 Category: Dermatology Authors: Thaҫi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K Tags: Br J Dermatol Source Type: research